SC-102

SC-102 is a peptide-drug conjugate from ConjuStar Biologics. A peptide-drug conjugate made of an EphA2-targeting peptide, a tubulin-inhibitor payload and a protease-cleavable linker. Its furthest stage is phase 1, for ephA2-expressing advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. US FDA IND clearance announced 4 June 2025 (company news); phase 1 recruiting (NCT06710158). Whether it works in people has not been established unless a trial below reports it.